Free Trial
→ Trump Treasure April 19 (From Paradigm Press) (Ad) Buy DYN Stock  Free DYN Stock Alerts

Dyne Therapeutics (DYN) Financials

Dyne Therapeutics logo
$6.98 -0.57 (-7.55%)
Closing price 04/10/2025 04:00 PM Eastern
Extended Trading
$6.84 -0.15 (-2.08%)
As of 08:33 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.
Compare
Annual Income Statements for Dyne Therapeutics

Annual Income Statements for Dyne Therapeutics

This table shows Dyne Therapeutics' income and expenses over time, based on annual financial data. All values are USD millions unless otherwise specified.

Metric 2019 2020 2021 2022 2023 2024
Net Income / (Loss) Attributable to Common Shareholders		 -15 -59 -149 -168 -236 -317
Consolidated Net Income / (Loss)		 -15 -59 -149 -168 -236 -317
Net Income / (Loss) Continuing Operations		 -15 -59 -149 -168 -236 -317
Total Pre-Tax Income 		-15 -59 -149 -168 -236 -317
Total Operating Income		 -14 -59 -150 -171 -242 -344
Total Gross Profit		 0.00 0.00 0.00 0.00 0.00 0.00
Total Revenue		 0.00 0.00 0.00 0.00 0.00 0.00
Total Cost of Revenue		 0.00 0.00 0.00 0.00 0.00 0.00
Total Operating Expenses		 14 59 150 171 242 344
Selling, General & Admin Expense		 2.79 13 29 28 31 62
Research & Development Expense		 11 45 121 143 211 281
Total Other Income / (Expense), net		 -1.03 0.11 0.73 2.86 6.23 26
Interest & Investment Income		 0.29 0.06 0.74 2.92 7.64 27
Other Income / (Expense), net		 -1.32 0.45 -0.01 -0.05 -1.42 -0.45
Basic Earnings per Share		 ($6.08) ($4.13) ($2.93) ($3.23) ($3.95) ($3.37)
Weighted Average Basic Shares Outstanding		 2.44M 14.40M 50.90M 51.98M 59.68M 94.14M
Diluted Earnings per Share		 ($6.08) ($4.13) ($2.93) ($3.23) ($3.95) ($3.37)
Weighted Average Diluted Shares Outstanding		 2.44M 14.40M 50.90M 51.98M 59.68M 94.14M
Weighted Average Basic & Diluted Shares Outstanding		 2.44M 14.40M 50.90M 51.98M 59.68M 94.14M

Quarterly Income Statements for Dyne Therapeutics

This table shows Dyne Therapeutics' income and expenses over time, based on quarterly financial data. All values are USD millions unless otherwise specified.

Metric Q3 2022 Q4 2022 Q1 2023 Q2 2023 Q3 2023 Q4 2023 Q1 2024 Q2 2024 Q3 2024 Q4 2024
Net Income / (Loss) Attributable to Common Shareholders		 -41 -38 -44 -65 -60 -67 -66 -65 -97 -90
Consolidated Net Income / (Loss)		 -41 -39 -44 -65 -60 -67 -66 -65 -97 -90
Net Income / (Loss) Continuing Operations		 -41 -40 -44 -65 -60 -67 -66 -65 -97 -90
Total Pre-Tax Income 		-41 -39 -44 -65 -60 -67 -66 -65 -97 -90
Total Operating Income		 -42 -40 -45 -67 -62 -68 -69 -72 -106 -97
Total Operating Expenses		 42 40 45 67 62 68 69 72 106 97
Selling, General & Admin Expense		 7.61 6.96 7.93 7.61 7.02 8.84 25 9.70 13 15
Research & Development Expense		 35 33 38 59 55 59 45 62 93 82
Total Other Income / (Expense), net		 0.89 1.09 1.28 1.83 2.06 1.05 3.51 6.86 8.53 7.57
Interest & Investment Income		 0.90 1.34 1.49 2.21 2.19 1.75 3.00 7.05 9.28 7.59
Other Income / (Expense), net		 -0.01 -0.26 -0.22 -0.37 -0.13 -0.70 0.51 -0.19 -0.74 -0.03
Basic Earnings per Share		 ($0.80) ($0.73) ($0.78) ($1.08) ($0.99) ($1.10) ($0.81) ($0.70) ($0.96) ($0.90)
Weighted Average Basic Shares Outstanding		 51.80M 51.98M 56.33M 59.84M 61.11M 59.68M 81.04M 92.51M 100.88M 94.14M
Diluted Earnings per Share		 ($0.80) ($0.73) ($0.78) ($1.08) ($0.99) ($1.10) ($0.81) ($0.70) ($0.96) ($0.90)
Weighted Average Diluted Shares Outstanding		 51.80M 51.98M 56.33M 59.84M 61.11M 59.68M 81.04M 92.51M 100.88M 94.14M
Weighted Average Basic & Diluted Shares Outstanding		 51.80M 51.98M 56.33M 59.84M 61.11M 59.68M 81.04M 92.51M 100.88M 94.14M

Annual Cash Flow Statements for Dyne Therapeutics

This table details how cash moves in and out of Dyne Therapeutics' business through operations, investing, and financing, using annual figures. All values are USD millions unless otherwise specified.

Metric 2019 2020 2021 2022 2023 2024
Net Change in Cash & Equivalents		 6.51 288 -100 -29 -51 313
Net Cash From Operating Activities		 -12 -47 -120 -154 -188 -292
Net Cash From Continuing Operating Activities		 -12 -47 -120 -154 -188 -292
Net Income / (Loss) Continuing Operations		 -15 -59 -149 -168 -236 -317
Consolidated Net Income / (Loss)		 -15 -59 -149 -168 -236 -317
Depreciation Expense		 0.27 0.70 1.09 1.68 1.67 1.67
Amortization Expense		 0.00 0.08 2.58 1.28 -1.10 -3.60
Non-Cash Adjustments To Reconcile Net Income		 1.35 6.14 14 17 21 46
Changes in Operating Assets and Liabilities, net		 1.41 5.11 12 -5.38 26 -19
Net Cash From Investing Activities		 -1.65 -46 -138 87 83 -204
Net Cash From Continuing Investing Activities		 -1.65 -46 -138 87 83 -204
Purchase of Property, Plant & Equipment		 -1.65 -1.16 -3.62 -3.07 -0.73 -2.38
Purchase of Investments		 0.00 -45 -237 -121 -44 -317
Sale and/or Maturity of Investments		 - 0.00 102 211 128 116
Net Cash From Financing Activities		 20 381 158 37 54 810
Net Cash From Continuing Financing Activities		 20 381 158 37 54 810
Issuance of Common Equity		 0.00 246 157 37 52 773
Other Financing Activities, net		 0.00 -0.42 0.58 0.53 1.95 37

Quarterly Cash Flow Statements for Dyne Therapeutics

This table details how cash moves in and out of Dyne Therapeutics' business through operations, investing, and financing, using quarterly figures. All values are USD millions unless otherwise specified.

Metric Q3 2022 Q4 2022 Q1 2023 Q2 2023 Q3 2023 Q4 2023 Q1 2024 Q2 2024 Q3 2024 Q4 2024
Net Change in Cash & Equivalents		 8.92 27 8.97 -14 -37 -8.66 150 336 -76 -97
Net Cash From Operating Activities		 -43 -29 -47 -56 -51 -35 -79 -55 -75 -84
Net Cash From Continuing Operating Activities		 -43 -29 -47 -56 -51 -35 -79 -55 -75 -84
Net Income / (Loss) Continuing Operations		 -41 -39 -44 -65 -60 -67 -66 -65 -97 -90
Consolidated Net Income / (Loss)		 -41 -39 -44 -65 -60 -67 -66 -65 -97 -90
Depreciation Expense		 0.40 0.40 0.41 0.43 0.43 0.40 0.39 0.40 0.44 0.45
Amortization Expense		 0.24 0.03 -0.18 -0.36 -0.37 -0.19 -0.52 -1.27 -0.98 -0.84
Non-Cash Adjustments To Reconcile Net Income		 3.10 4.05 4.95 4.99 5.04 5.90 20 6.86 8.88 11
Changes in Operating Assets and Liabilities, net		 -5.16 5.16 -7.92 4.20 4.50 26 -33 4.24 14 -5.09
Net Cash From Investing Activities		 52 19 27 17 13 26 -180 11 -19 -16
Net Cash From Continuing Investing Activities		 52 19 27 17 13 26 -180 11 -19 -16
Purchase of Property, Plant & Equipment		 -0.89 -0.52 -0.23 -0.25 -0.17 -0.08 -0.19 -0.86 -0.25 -1.08
Purchase of Investments		 -5.18 -26 -17 -18 -9.58 - -181 -26 -57 -53
Sale and/or Maturity of Investments		 58 46 44 35 23 26 1.74 38 38 38
Net Cash From Financing Activities		 0.07 37 29 25 0.45 0.15 408 380 18 3.64
Net Cash From Continuing Financing Activities		 0.07 37 29 25 0.45 0.15 408 380 18 3.64
Other Financing Activities, net		 0.07 0.34 0.59 0.76 0.45 0.15 11 4.28 18 3.64

Annual Balance Sheets for Dyne Therapeutics

This table presents Dyne Therapeutics' assets and liabilities at the end of each period, using annual balance sheet data. All values are USD millions unless otherwise specified.

Metric 2019 2020 2021 2022 2023 2024
Total Assets		 16 353 426 306 165 691
Total Current Assets		 15 349 382 266 129 659
Cash & Equivalents		 15 301 201 172 122 435
Short-Term Investments		 0.00 44 176 84 1.47 207
Prepaid Expenses		 0.13 3.77 5.82 9.58 6.28 17
Plant, Property, & Equipment, net		 1.49 1.95 4.68 5.95 4.78 5.40
Total Noncurrent Assets		 0.19 2.30 39 35 31 27
Other Noncurrent Operating Assets		 0.19 2.30 39 35 31 27
Total Liabilities & Shareholders' Equity		 16 353 426 306 165 691
Total Liabilities		 2.40 11 57 54 74 61
Total Current Liabilities		 2.36 11 29 28 51 42
Accounts Payable		 1.26 3.44 4.03 5.26 23 6.56
Accrued Expenses		 1.10 7.53 21 18 23 31
Other Current Liabilities		 - 0.00 3.89 4.61 4.72 4.85
Total Noncurrent Liabilities		 0.04 0.00 29 26 23 19
Other Noncurrent Operating Liabilities		 - 0.00 29 26 23 19
Commitments & Contingencies		 0.00 0.00 0.00 0.00 0.00 0.00
Total Equity & Noncontrolling Interests		 14 342 368 252 91 630
Total Preferred & Common Equity		 14 342 368 252 91 630
Preferred Stock		 27 0.00 0.00 0.00 0.00 0.00
Total Common Equity		 -13 342 368 252 91 630
Common Stock		 6.35 422 597 650 724 1,580
Retained Earnings		 -20 -79 -228 -397 -633 -950
Accumulated Other Comprehensive Income / (Loss)		 0.00 -0.03 -0.27 -0.57 0.00 0.01

Quarterly Balance Sheets for Dyne Therapeutics

This table presents Dyne Therapeutics' assets and liabilities at the end of each period, using quarterly balance sheet data. All values are USD millions unless otherwise specified.

Metric Q1 2023 Q2 2023 Q3 2023 Q1 2024 Q2 2024 Q3 2024
Total Assets		 289 251 205 522 826 769
Total Current Assets		 249 213 168 488 792 736
Cash & Equivalents		 181 168 130 272 608 532
Short-Term Investments		 57 40 28 182 171 192
Prepaid Expenses		 11 5.44 10 35 13 13
Plant, Property, & Equipment, net		 5.57 5.36 5.11 4.58 5.02 4.90
Total Noncurrent Assets		 34 33 32 30 29 28
Other Noncurrent Operating Assets		 34 33 32 30 29 28
Total Liabilities & Shareholders' Equity		 289 251 205 522 826 769
Total Liabilities		 47 45 53 44 51 63
Total Current Liabilities		 22 20 30 22 30 43
Accounts Payable		 8.77 2.72 3.55 7.21 1.89 6.16
Accrued Expenses		 8.17 13 21 10 23 32
Other Current Liabilities		 4.64 4.71 4.71 4.76 4.78 4.81
Total Noncurrent Liabilities		 25 24 24 22 21 20
Other Noncurrent Operating Liabilities		 25 - - 22 - 20
Commitments & Contingencies		 0.00 0.00 0.00 0.00 0.00 0.00
Total Equity & Noncontrolling Interests		 242 207 152 478 775 706
Total Preferred & Common Equity		 242 207 152 478 775 706
Preferred Stock		 0.00 0.00 0.00 0.00 0.00 0.00
Total Common Equity		 242 207 152 478 775 706
Common Stock		 683 713 718 1,176 1,539 1,565
Retained Earnings		 -441 -506 -566 -698 -763 -860
Accumulated Other Comprehensive Income / (Loss)		 -0.20 -0.06 -0.01 -0.13 -0.24 0.48

Annual Metrics and Ratios for Dyne Therapeutics

This table displays calculated financial ratios and metrics derived from Dyne Therapeutics' official financial filings.

Metric 2019 2020 2021 2022 2023 2024
Growth Metrics		 - - - - - -
Revenue Growth		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
EBITDA Growth		 0.00% -285.95% -154.90% -14.82% -44.60% -42.49%
EBIT Growth		 0.00% -284.16% -157.80% -13.99% -42.43% -41.37%
NOPAT Growth		 0.00% -324.18% -155.81% -13.96% -41.65% -42.01%
Net Income Growth		 0.00% -300.01% -151.18% -12.60% -40.36% -34.54%
EPS Growth		 0.00% 32.07% 29.06% -10.24% -22.29% 14.68%
Operating Cash Flow Growth		 0.00% -293.00% -157.08% -28.51% -22.46% -55.38%
Free Cash Flow Firm Growth		 0.00% 0.00% -157.33% -24.91% -13.63% -84.01%
Invested Capital Growth		 0.00% -394.46% -184.15% 56.44% -771.93% 60.92%
Revenue Q/Q Growth		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
EBITDA Q/Q Growth		 0.00% 0.00% -18.25% 0.00% -13.14% -9.26%
EBIT Q/Q Growth		 0.00% 0.00% -18.45% 0.00% -12.98% -9.11%
NOPAT Q/Q Growth		 0.00% 0.00% -18.44% 0.00% -12.83% -9.36%
Net Income Q/Q Growth		 0.00% 0.00% -18.34% 0.00% -13.36% -7.78%
EPS Q/Q Growth		 0.00% 0.00% -1,727.78% 0.00% -10.34% 5.60%
Operating Cash Flow Q/Q Growth		 0.00% -52.56% -7.20% 0.00% -3.19% -20.30%
Free Cash Flow Firm Q/Q Growth		 0.00% 0.00% 0.00% -1,986.84% 15.84% -41.16%
Invested Capital Q/Q Growth		 0.00% 0.00% -227.01% 0.00% -279.41% 31.45%
Profitability Metrics		 - - - - - -
Gross Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
EBITDA Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Operating Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
EBIT Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Profit (Net Income) Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Tax Burden Percent		 100.00% 101.54% 100.00% 100.00% 100.00% 100.00%
Interest Burden Percent		 98.09% 100.58% 99.51% 98.29% 96.86% 92.18%
Effective Tax Rate		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Invested Capital (ROIC)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
ROIC Less NNEP Spread (ROIC-NNEP)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Net Nonoperating Assets (RNNOA)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Equity (ROE)		 -105.86% -33.35% -42.02% -54.18% -137.31% -88.03%
Cash Return on Invested Capital (CROIC)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Operating Return on Assets (OROA)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Assets (ROA)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Common Equity (ROCE)		 101.01% -30.79% -42.02% -54.18% -137.31% -88.03%
Return on Equity Simple (ROE_SIMPLE)		 -105.86% -17.36% -40.55% -66.61% -258.44% -50.40%
Net Operating Profit after Tax (NOPAT)		 -9.68 -41 -105 -120 -170 -241
NOPAT Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Net Nonoperating Expense Percent (NNEP)		 -35.41% -10.21% -12.27% -15.31% -35.04% -20.04%
Return On Investment Capital (ROIC_SIMPLE)		 - - - -47.42% -185.68% -38.22%
Cost of Revenue to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
SG&A Expenses to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
R&D to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Operating Expenses to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Earnings before Interest and Taxes (EBIT)		 -15 -58 -150 -171 -244 -344
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)		 -15 -57 -146 -168 -243 -346
Valuation Ratios		 - - - - - -
Price to Book Value (P/BV)		 0.00 2.79 1.66 2.38 8.94 3.81
Price to Tangible Book Value (P/TBV)		 0.00 2.79 1.66 2.38 8.94 3.81
Price to Revenue (P/Rev)		 0.00 0.00 0.00 0.00 0.00 0.00
Price to Earnings (P/E)		 0.00 0.00 0.00 0.00 0.00 0.00
Dividend Yield		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Earnings Yield		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Enterprise Value to Invested Capital (EV/IC)		 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Revenue (EV/Rev)		 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to EBITDA (EV/EBITDA)		 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to EBIT (EV/EBIT)		 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to NOPAT (EV/NOPAT)		 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Operating Cash Flow (EV/OCF)		 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Free Cash Flow (EV/FCFF)		 0.00 0.00 0.00 0.00 0.00 0.00
Leverage & Solvency		 - - - - - -
Debt to Equity		 0.00 0.00 0.00 0.00 0.00 0.00
Long-Term Debt to Equity		 0.00 0.00 0.00 0.00 0.00 0.00
Financial Leverage		 -1.04 -1.01 -1.02 -1.02 -1.10 -1.06
Leverage Ratio		 1.17 1.04 1.10 1.18 1.37 1.19
Compound Leverage Factor		 1.15 1.04 1.09 1.16 1.33 1.09
Debt to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Short-Term Debt to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Long-Term Debt to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Preferred Equity to Total Capital		 195.42% 0.00% 0.00% 0.00% 0.00% 0.00%
Noncontrolling Interests to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Common Equity to Total Capital		 -95.42% 100.00% 100.00% 100.00% 100.00% 100.00%
Debt to EBITDA		 0.00 0.00 0.00 0.00 0.00 0.00
Net Debt to EBITDA		 0.00 0.00 0.00 0.00 0.00 0.00
Long-Term Debt to EBITDA		 0.00 0.00 0.00 0.00 0.00 0.00
Debt to NOPAT		 0.00 0.00 0.00 0.00 0.00 0.00
Net Debt to NOPAT		 0.00 0.00 0.00 0.00 0.00 0.00
Long-Term Debt to NOPAT		 0.00 0.00 0.00 0.00 0.00 0.00
Altman Z-Score		 54.38 52.50 5.48 3.95 -3.03 20.93
Noncontrolling Interest Sharing Ratio		 195.42% 7.70% 0.00% 0.00% 0.00% 0.00%
Liquidity Ratios		 - - - - - -
Current Ratio		 6.26 31.83 13.31 9.46 2.53 15.60
Quick Ratio		 6.21 31.49 13.11 9.11 2.41 15.20
Cash Flow Metrics		 - - - - - -
Free Cash Flow to Firm (FCFF)		 0.00 -39 -100 -124 -141 -260
Operating Cash Flow to CapEx		 -718.52% -4,005.86% -3,304.67% -5,009.62% -25,810.43% -12,305.09%
Free Cash Flow to Firm to Interest Expense		 0.00 -97.73 0.00 0.00 0.00 0.00
Operating Cash Flow to Interest Expense		 0.00 -117.44 0.00 0.00 0.00 0.00
Operating Cash Flow Less CapEx to Interest Expense		 0.00 -120.38 0.00 0.00 0.00 0.00
Efficiency Ratios		 - - - - - -
Asset Turnover		 0.00 0.00 0.00 0.00 0.00 0.00
Accounts Receivable Turnover		 0.00 0.00 0.00 0.00 0.00 0.00
Inventory Turnover		 0.00 0.00 0.00 0.00 0.00 0.00
Fixed Asset Turnover		 0.00 0.00 0.00 0.00 0.00 0.00
Accounts Payable Turnover		 0.00 0.00 0.00 0.00 0.00 0.00
Days Sales Outstanding (DSO)		 0.00 0.00 0.00 0.00 0.00 0.00
Days Inventory Outstanding (DIO)		 0.00 0.00 0.00 0.00 0.00 0.00
Days Payable Outstanding (DPO)		 0.00 0.00 0.00 0.00 0.00 0.00
Cash Conversion Cycle (CCC)		 0.00 0.00 0.00 0.00 0.00 0.00
Capital & Investment Metrics		 - - - - - -
Invested Capital		 -0.60 -2.95 -8.37 -3.65 -32 -12
Invested Capital Turnover		 0.00 0.00 0.00 0.00 0.00 0.00
Increase / (Decrease) in Invested Capital		 0.00 -2.35 -5.43 4.73 -28 19
Enterprise Value (EV)		 246 609 236 344 693 1,755
Market Capitalization		 233 954 613 600 816 2,398
Book Value per Share		 ($5.48) $7.53 $7.15 $4.86 $1.49 $6.19
Tangible Book Value per Share		 ($5.48) $7.53 $7.15 $4.86 $1.49 $6.19
Total Capital		 14 342 368 252 91 630
Total Debt		 0.00 0.00 0.00 0.00 0.00 0.00
Total Long-Term Debt		 0.00 0.00 0.00 0.00 0.00 0.00
Net Debt		 -15 -345 -377 -256 -123 -642
Capital Expenditures (CapEx)		 1.65 1.16 3.62 3.07 0.73 2.38
Debt-free, Cash-free Net Working Capital (DFCFNWC)		 -2.23 -7.19 -23 -19 -45 -25
Debt-free Net Working Capital (DFNWC)		 12 338 354 238 78 617
Net Working Capital (NWC)		 12 338 354 238 78 617
Net Nonoperating Expense (NNE)		 5.18 18 44 48 66 77
Net Nonoperating Obligations (NNO)		 -15 -345 -377 -256 -123 -642
Total Depreciation and Amortization (D&A)		 0.27 0.78 3.67 2.96 0.57 -1.93
Debt-free, Cash-free Net Working Capital to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Debt-free Net Working Capital to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Net Working Capital to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Earnings Adjustments		 - - - - - -
Adjusted Basic Earnings per Share		 $0.00 ($4.13) ($2.93) ($3.23) ($3.95) ($3.37)
Adjusted Weighted Average Basic Shares Outstanding		 0.00 51.46M 51.64M 56.34M 59.68M 94.14M
Adjusted Diluted Earnings per Share		 $0.00 ($4.13) ($2.93) ($3.23) ($3.95) ($3.37)
Adjusted Weighted Average Diluted Shares Outstanding		 0.00 51.46M 51.64M 51.98M 59.68M 94.14M
Adjusted Basic & Diluted Earnings per Share		 $0.00 ($4.13) ($2.93) $0.00 $0.00 $0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding		 0.00 14.40M 50.90M 51.98M 59.68M 94.14M
Normalized Net Operating Profit after Tax (NOPAT)		 -9.68 -41 -105 -120 -170 -241
Normalized NOPAT Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Pre Tax Income Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Debt Service Ratios		 - - - - - -
EBIT to Interest Expense		 0.00 -146.96 0.00 0.00 0.00 0.00
NOPAT to Interest Expense		 0.00 -103.67 0.00 0.00 0.00 0.00
EBIT Less CapEx to Interest Expense		 0.00 -149.89 0.00 0.00 0.00 0.00
NOPAT Less CapEx to Interest Expense		 0.00 -106.60 0.00 0.00 0.00 0.00
Payout Ratios		 - - - - - -
Dividend Payout Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Augmented Payout Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%

Quarterly Metrics and Ratios for Dyne Therapeutics

This table displays calculated financial ratios and metrics derived from Dyne Therapeutics' official financial filings.

Metric Q3 2022 Q4 2022 Q1 2023 Q2 2023 Q3 2023 Q4 2023 Q1 2024 Q2 2024 Q3 2024 Q4 2024
Growth Metrics		 - - - - - - - - - -
Revenue Growth		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
EBITDA Growth		 0.37% 0.00% -31.53% -29.22% -49.64% -70.59% -51.35% -8.93% -71.56% -43.02%
EBIT Growth		 1.12% 0.00% -28.38% -27.23% -47.56% -69.28% -50.29% -7.52% -70.52% -42.03%
NOPAT Growth		 1.14% 0.00% -27.05% -26.50% -47.29% -68.61% -52.11% -7.83% -69.67% -43.46%
Net Income Growth		 0.00% 0.00% -24.18% -24.09% -45.49% -71.63% -48.57% -0.31% -61.31% -34.37%
EPS Growth		 0.00% 0.00% -13.04% -6.93% -23.75% -50.68% -3.85% 35.19% 3.03% 18.18%
Operating Cash Flow Growth		 -58.82% 0.00% 7.55% -80.02% -18.22% -19.92% -67.43% 1.39% -47.48% -140.92%
Free Cash Flow Firm Growth		 41.55% -704.89% 48.50% -395.04% -166.58% 41.44% -211.13% 41.04% 37.87% -354.44%
Invested Capital Growth		 -100.00% 56.44% -72.02% 591.04% 0.00% -771.93% 558.11% -26.31% -202.28% 60.92%
Revenue Q/Q Growth		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
EBITDA Q/Q Growth		 19.71% 4.04% -13.70% -47.51% 7.02% -9.39% -0.88% -6.16% -46.44% 8.81%
EBIT Q/Q Growth		 19.83% 4.46% -13.07% -46.91% 7.02% -9.60% -0.38% -5.10% -47.46% 8.71%
NOPAT Q/Q Growth		 19.86% 5.05% -13.25% -46.79% 6.69% -8.70% -2.17% -4.06% -46.83% 8.09%
Net Income Q/Q Growth		 20.88% 6.18% -13.80% -46.88% 7.23% -10.68% 1.48% 0.83% -49.19% 7.81%
EPS Q/Q Growth		 20.79% 8.75% -6.85% -38.46% 8.33% -11.11% 26.36% 13.58% -37.14% 6.25%
Operating Cash Flow Q/Q Growth		 -38.49% 31.80% -60.69% -18.62% 9.06% 30.82% -124.35% 30.14% -36.02% -13.01%
Free Cash Flow Firm Q/Q Growth		 -51.91% -42.71% 32.25% -237.06% 18.20% 68.65% -65.07% 36.12% 13.80% -129.28%
Invested Capital Q/Q Growth		 100.00% 0.00% 202.08% 530.16% -24.45% -279.41% 368.93% -29.44% -204.86% 31.45%
Profitability Metrics		 - - - - - - - - - -
Gross Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
EBITDA Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Operating Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
EBIT Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Profit (Net Income) Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Tax Burden Percent		 100.00% 99.41% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00%
Interest Burden Percent		 97.86% 96.68% 96.73% 96.71% 96.49% 97.44% 95.63% 90.23% 91.28% 92.18%
Effective Tax Rate		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Invested Capital (ROIC)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
ROIC Less NNEP Spread (ROIC-NNEP)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Net Nonoperating Assets (RNNOA)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Equity (ROE)		 0.00% -54.18% -61.10% -76.65% -273.78% -137.31% -71.50% -52.46% -68.69% -88.03%
Cash Return on Invested Capital (CROIC)		 200.00% 0.00% -1,372.22% -700.91% -1,894.77% 0.00% -1,465.59% -900.80% 0.00% 0.00%
Operating Return on Assets (OROA)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Assets (ROA)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Common Equity (ROCE)		 0.00% -54.18% -61.10% -76.65% -273.78% -137.31% -71.50% -52.46% -68.69% -88.03%
Return on Equity Simple (ROE_SIMPLE)		 0.00% 0.00% -73.04% -91.50% -136.89% 0.00% -53.84% -33.23% -41.74% 0.00%
Net Operating Profit after Tax (NOPAT)		 -30 -28 -32 -47 -44 -47 -48 -50 -74 -68
NOPAT Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Net Nonoperating Expense Percent (NNEP)		 -5.79% -3.39% -4.40% -7.65% -24.75% -10.16% -4.98% -3.13% -5.40% -5.64%
Return On Investment Capital (ROIC_SIMPLE)		 - -11.14% - - - -51.90% - - - -10.79%
Cost of Revenue to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
SG&A Expenses to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
R&D to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Operating Expenses to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Earnings before Interest and Taxes (EBIT)		 -42 -40 -46 -67 -62 -68 -69 -72 -106 -97
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)		 -42 -40 -45 -67 -62 -68 -69 -73 -107 -98
Valuation Ratios		 - - - - - - - - - -
Price to Book Value (P/BV)		 0.00 2.38 2.68 3.17 3.60 8.94 4.87 3.98 5.11 3.81
Price to Tangible Book Value (P/TBV)		 0.00 2.38 2.68 3.17 3.60 8.94 4.87 3.98 5.11 3.81
Price to Revenue (P/Rev)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Price to Earnings (P/E)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Dividend Yield		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Earnings Yield		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Enterprise Value to Invested Capital (EV/IC)		 0.00 0.00 110.31 20.14 23.26 0.00 76.43 134.50 0.00 0.00
Enterprise Value to Revenue (EV/Rev)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to EBITDA (EV/EBITDA)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to EBIT (EV/EBIT)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to NOPAT (EV/NOPAT)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Operating Cash Flow (EV/OCF)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Free Cash Flow (EV/FCFF)		 99.71 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Leverage & Solvency		 - - - - - - - - - -
Debt to Equity		 0.00 0.00 0.00 0.12 0.15 0.00 0.00 0.03 0.00 0.00
Long-Term Debt to Equity		 0.00 0.00 0.00 0.12 0.15 0.00 0.00 0.03 0.00 0.00
Financial Leverage		 -0.98 -1.02 -0.97 -0.96 -0.88 -1.10 -0.96 -0.96 -1.00 -1.06
Leverage Ratio		 1.13 1.18 1.17 1.20 1.35 1.37 1.13 1.10 1.14 1.19
Compound Leverage Factor		 1.10 1.14 1.13 1.16 1.30 1.34 1.08 0.99 1.04 1.09
Debt to Total Capital		 0.00% 0.00% 0.00% 10.52% 13.39% 0.00% 0.00% 2.63% 0.00% 0.00%
Short-Term Debt to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Long-Term Debt to Total Capital		 0.00% 0.00% 0.00% 10.52% 13.39% 0.00% 0.00% 2.63% 0.00% 0.00%
Preferred Equity to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Noncontrolling Interests to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Common Equity to Total Capital		 0.00% 100.00% 100.00% 89.48% 86.61% 100.00% 100.00% 97.37% 100.00% 100.00%
Debt to EBITDA		 0.00 0.00 0.00 -0.13 -0.11 0.00 0.00 -0.08 0.00 0.00
Net Debt to EBITDA		 0.00 0.00 0.00 0.94 0.63 0.00 0.00 2.78 0.00 0.00
Long-Term Debt to EBITDA		 0.00 0.00 0.00 -0.13 -0.11 0.00 0.00 -0.08 0.00 0.00
Debt to NOPAT		 0.00 0.00 0.00 -0.18 -0.16 0.00 0.00 -0.11 0.00 0.00
Net Debt to NOPAT		 0.00 0.00 0.00 1.35 0.89 0.00 0.00 3.99 0.00 0.00
Long-Term Debt to NOPAT		 0.00 0.00 0.00 -0.18 -0.16 0.00 0.00 -0.11 0.00 0.00
Altman Z-Score		 0.00 5.35 6.62 6.06 2.11 0.48 30.33 36.03 33.24 22.11
Noncontrolling Interest Sharing Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Liquidity Ratios		 - - - - - - - - - -
Current Ratio		 0.00 9.46 11.54 10.54 5.67 2.53 21.83 26.63 17.02 15.60
Quick Ratio		 0.00 9.11 11.03 10.27 5.32 2.41 20.28 26.18 16.73 15.20
Cash Flow Metrics		 - - - - - - - - - -
Free Cash Flow to Firm (FCFF)		 -23 -33 -22 -75 -61 -19 -69 -44 -38 -87
Operating Cash Flow to CapEx		 -4,831.26% -5,624.66% -20,394.78% -22,256.80% -30,300.60% -42,690.24% -41,118.85% -6,402.33% -29,497.63% -7,845.12%
Free Cash Flow to Firm to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Operating Cash Flow to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Operating Cash Flow Less CapEx to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Efficiency Ratios		 - - - - - - - - - -
Asset Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Accounts Receivable Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Inventory Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Fixed Asset Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Accounts Payable Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Days Sales Outstanding (DSO)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Days Inventory Outstanding (DIO)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Days Payable Outstanding (DPO)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Cash Conversion Cycle (CCC)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Capital & Investment Metrics		 - - - - - - - - - -
Invested Capital		 0.00 -3.65 3.72 23 18 -32 25 17 -18 -12
Invested Capital Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Increase / (Decrease) in Invested Capital		 -6.59 4.73 -9.59 28 18 -28 21 -6.17 -36 19
Enterprise Value (EV)		 657 344 411 473 412 693 1,873 2,326 2,883 1,755
Market Capitalization		 657 600 649 656 547 816 2,327 3,084 3,606 2,398
Book Value per Share		 $0.00 $4.86 $4.29 $3.55 $2.49 $1.49 $5.83 $8.87 $7.03 $6.19
Tangible Book Value per Share		 $0.00 $4.86 $4.29 $3.55 $2.49 $1.49 $5.83 $8.87 $7.03 $6.19
Total Capital		 0.00 252 242 231 176 91 478 796 706 630
Total Debt		 0.00 0.00 0.00 24 24 0.00 0.00 21 0.00 0.00
Total Long-Term Debt		 0.00 0.00 0.00 24 24 0.00 0.00 21 0.00 0.00
Net Debt		 0.00 -256 -238 -183 -134 -123 -454 -758 -724 -642
Capital Expenditures (CapEx)		 0.89 0.52 0.23 0.25 0.17 0.08 0.19 0.86 0.25 1.08
Debt-free, Cash-free Net Working Capital (DFCFNWC)		 0.00 -19 -11 -15 -19 -45 12 -16 -31 -25
Debt-free Net Working Capital (DFNWC)		 0.00 238 228 193 139 78 466 763 693 617
Net Working Capital (NWC)		 0.00 238 228 193 139 78 466 763 693 617
Net Nonoperating Expense (NNE)		 12 11 12 18 17 19 17 15 23 22
Net Nonoperating Obligations (NNO)		 0.00 -256 -238 -183 -134 -123 -454 -758 -724 -642
Total Depreciation and Amortization (D&A)		 0.63 0.43 0.23 0.07 0.07 0.21 -0.14 -0.87 -0.54 -0.39
Debt-free, Cash-free Net Working Capital to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Debt-free Net Working Capital to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Net Working Capital to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Earnings Adjustments		 - - - - - - - - - -
Adjusted Basic Earnings per Share		 $0.00 ($0.73) ($0.78) ($1.08) ($0.99) ($1.10) ($0.81) ($0.70) ($0.96) ($0.90)
Adjusted Weighted Average Basic Shares Outstanding		 0.00 51.98M 56.33M 59.84M 61.11M 59.68M 81.04M 92.51M 100.88M 94.14M
Adjusted Diluted Earnings per Share		 $0.00 ($0.73) ($0.78) ($1.08) ($0.99) ($1.10) ($0.81) ($0.70) ($0.96) ($0.90)
Adjusted Weighted Average Diluted Shares Outstanding		 0.00 51.98M 56.33M 59.84M 61.11M 59.68M 81.04M 92.51M 100.88M 94.14M
Adjusted Basic & Diluted Earnings per Share		 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding		 0.00 51.98M 56.33M 59.84M 61.11M 59.68M 81.04M 92.51M 100.88M 94.14M
Normalized Net Operating Profit after Tax (NOPAT)		 -30 -28 -32 -47 -44 -47 -48 -50 -74 -68
Normalized NOPAT Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Pre Tax Income Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Debt Service Ratios		 - - - - - - - - - -
EBIT to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
NOPAT to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
EBIT Less CapEx to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
NOPAT Less CapEx to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Payout Ratios		 - - - - - - - - - -
Dividend Payout Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Augmented Payout Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%

Frequently Asked Questions About Dyne Therapeutics' Financials

When does Dyne Therapeutics's financial year end?

According to the most recent income statement we have on file, Dyne Therapeutics' fiscal year ends in December. Their fiscal year 2024 ended on December 31, 2024.

How has Dyne Therapeutics' net income changed over the last 5 years?

Dyne Therapeutics' net income appears to be on an upward trend, with a most recent value of -$317.42 million in 2024, rising from -$14.86 million in 2019. The previous period was -$235.94 million in 2023.

What is Dyne Therapeutics's operating income?
Dyne Therapeutics's total operating income in 2024 was -$343.89 million, based on the following breakdown:
  • Total Gross Profit: $0.00
  • Total Operating Expenses: $343.89 million
How has Dyne Therapeutics revenue changed over the last 5 years?

Over the last 5 years, Dyne Therapeutics' total revenue changed from $0.00 in 2019 to $0.00 in 2024, a change of 0.0%.

How much debt does Dyne Therapeutics have?

Dyne Therapeutics' total liabilities were at $61.40 million at the end of 2024, a 16.8% decrease from 2023, and a 2,458.2% increase since 2019.

How much cash does Dyne Therapeutics have?

In the past 5 years, Dyne Therapeutics' cash and equivalents has ranged from $14.63 million in 2019 to $435.45 million in 2024, and is currently $435.45 million as of their latest financial filing in 2024.

How has Dyne Therapeutics' book value per share changed over the last 5 years?

Over the last 5 years, Dyne Therapeutics' book value per share changed from -5.48 in 2019 to 6.19 in 2024, a change of -212.9%.

Remove Ads

Related Companies

This page (NASDAQ:DYN) was last updated on 4/11/2025 by MarketBeat.com Staff
From Our Partners
Crypto’s crashing…but we’re still profiting
Most traders are panicking right now. Bitcoin’s dropping. Altcoins are bleeding. The stock market’s a mess....
Crypto Swap Profits | Sponsored
Now I look stupid. Real stupid...
I thought what happened 25 years ago was a once- in-a-lifetime event… but how wrong I was. Because here we...
Porter & Company | Sponsored
“Fed Proof” Your Bank Account with THESE 4 Simple Steps
Starting as soon as a few months from now, the United States government will make a sweeping change to bank ac...
Weiss Ratings | Sponsored
Elon Musk Confirms: Tesla’s Optimus is Replacing Workers… and Heading to Mars
Elon Musk just confirmed Tesla’s robot will go to Mars. But on Earth, it may trigger a trillion-dollar tech sh...
InvestorPlace | Sponsored
Collect $7k per month from Tesla’s SECRET dividend
Tesla doesn't pay a traditional dividend.... But I just discovered a secret backdoor to collect a secret 69...
Investors Alley | Sponsored
Amazon Shocker
Jeff Bezos quietly backing world-changing tech (not AI) The Amazon founder is quietly advancing a radical t...
Stansberry Research | Sponsored
DOGE tax surprise
Elon Musk's DOGE agents have some very strange plans for the IRS... Recently, it emerged that our tax auth...
Altimetry | Sponsored
Caught on Camera: Elon Musk’s “Area 51”
You won’t believe what tech legend Jeff Brown found in what he calls Elon Musk’s “Area 51.” (Click here to see...
Brownstone Research | Sponsored